Efficacy and tolerability of 5- vs 10-day cefixime therapy in acute exacerbations of chronic bronchitis

Clinical Drug Investigation

Volumn 15, Issue 1, 1998, Pages 13-20

  Lorenz, J ^a   Steinfeld, P ^b   Drath, L ^c   Keienburg, T ^a   Troester, K ^b  

^a District Hospital Ludenscheid   (Germany)

^b MERCK KGAA   (Germany)

^c Drs Kapp and Breuer Laboratory   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CEFIXIME;

ADULT; AGED; ARTICLE; CHRONIC BRONCHITIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPUTUM ANALYSIS;

EID: 0031882688     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199815010-00002     Document Type: Article

References (20)

1. Verghese A, Roberson D, Kalbfleisch JH, et al. Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis. Antimicrob Agents Chemother 1990; 34: 1041-4
2. Davies BI. Critical review of microbiological data and methods in diagnosis of lower respiratory tract infections. Monaldi Arch Chest Dis 1994; 49: 52-6
3. Markham A, Brogden RN. Cefixime: a review of its therapeutic efficacy in low er respiratory tract infections. Drugs 1995; 49: 1007-22
4. Kiani R, Johnson D, Nelson B. Comparative, multicenter studies of cefixime and amoxicillin in the treatment of respiratory tract infections. Am J Med 1988; 85: 6-13
5. Dorow P. Safety and efficacy of cefixime versus cefaclor in respiratory tract infections. J Chemother 1989; 1: 257-60
6. Modai J. Efficacy and tolerability of cefixime in lower respiratory tract infections in adults: French multicentric study. Presse Med 1989; 18: 1605-7
7. Neu HC, Chick TW. Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. Chest 1993; 194: 1393-9
8. Cazzola M, Vinciguerra A, Beghi GF, et al. Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. J Chemother 1995; 7: 432-41
9. Quintiliani R. Cefixime in the treatment of patients with lower respiratory tract infections: results of US clinical trials. Clin Ther 1996; 18: 373-90
10. Cogo R, Monzani GP, Caiazzo G. Safety and efficacy of cefixime vs ceftriaxone in the treatment of infectious exacerbations of chronic bronchitis. J Drug Dev 1993; 6 Suppl. 1: 55-6
11. Stratton CW. Efficacy and safety of cefixime for the empiric therapy of acute bronchitis and AECB. Infect Med 1993; 10 Suppl. B: 11-15
12. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204
13. Dunnett CW, Gent M. Significance testing to establish equivalence between treatments, with special reference to data in the form of 2×2 tables. Biometrics 1977; 33: 593-602
14. Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley, 1981
15. Boudignat O, Zylbertrest R, Roche G. Etude comparative de deux schemas dadministration du cefixime dans le traitement des infections otorhinolaryngees ou bronchiques. Presse Med 1989; 18: 1622-5
16. Sclar DA, Tartaglione TA, Fine MJ. Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases. Infect Agents Dis 1994; 3: 266-73
17. Hendrickse WA, Kusmiesz H, Shelton S, et al. Five vs ten days of therapy for acute otitis media. Pediatr Infect Dis 1988; 7: 14-23
18. Portier H, Chavanet P, Waldner-Combernoux A, et al. Five versus ten days' treatment of streptococcal pharyngotonsillitis: a randomized controlled trial comparing cefpodoxime proxetil and phenoxymethyl penicillin. Scand J Infect Dis 1994; 26: 59-66
19. Henry D, Ruoff GE, Rhudy J, et al. Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis Antimicrob Agents Chemother 1995; 39: 2528-34
20. Schito GC, Mannelli S, Pesce A. Trends in the activity of macrolide and beta-lactam antibiotics and resistance development. Alexander Project Group. J Chemother 1997; 9 Suppl. 3: 18-28